Misplaced Pages

This is an old revision of this page, as edited by Beetstra (talk | contribs) at 22:13, 10 November 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank', 'ChEMBL').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cinacalcet

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a605004
License data	EU EMA: by INN US FDA: Cinacalcet
Pregnancy category	AU: B3
Routes of administration	Oral
ATC code	H05BX01 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	20 to 25% Increases if taken with food
Protein binding	93 to 97%
Metabolism	Hepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated)
Elimination half-life	30 to 40 hours
Excretion	Renal (80%) and fecal (15%)
Identifiers
IUPAC name (R)-N--3- propan-1-amine
CAS Number	226256-56-0
PubChem CID	156419
DrugBank	DB01012
ChemSpider	137743
UNII	UAZ6V7728S
KEGG	D03504
ChEBI	CHEBI:48390
CompTox Dashboard (EPA)	DTXSID8048286
ECHA InfoCard	100.208.116
Chemical and physical data
Formula	C22H22F3N
Molar mass	357.412 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c1cccc(c1)CCCN(c3c2ccccc2ccc3)C
InChI InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1 Key:VDHAWDNDOKGFTD-MRXNPFEDSA-N
(what is this?)  (verify)

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of having end-stage renal disease.. Cinacalcet is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Clinical uses

Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and hypercalcemia in patients with parathyroid carcinoma.

Synthesis

B.C. Van Wagenen, S.T. Moe, M.F. Balandrin, E.G. DelMar, E.F. Nemeth, U.S. patent 6,211,244 (2001).

References

1. Torres PU (2006). "Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease". Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 16 (3): 253–8. doi:10.1053/j.jrn.2006.04.010. PMID 16825031.
2. "Sensipar for Parathyroid Carcinoma". Amgen. 2009. Retrieved 25 September 2009.

External links

• Sensipar website run by Amgen
• Prescribing information (package insert)
• Cinacalcet - Medlineplus.org
• Cinacalcet - Drug Digest.

• Drugs